Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nitrofurantoin Macrocrystals · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Nitrofurantoin Macrocrystals 100 mg Capsules |
| 2 | ACTIVE_COMPARATOR | Macrodantin® 100 mg Capsules |
| Name | Type | Description |
|---|---|---|
| Nitrofurantoin Macrocrystals 100 mg Capsules | DRUG | 100mg, single dose fed |
| Macrodantin® 100 mg Capsules | DRUG | 100mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum Beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to of the study and on the evening prior to e...
Nitrofurantoin Macrocrystals is a small molecule drug developed by Viatris Inc. (ticker VTRS). It is also known as Nitrofurantoin Macrocrystals 100 mg Capsules. The drug has been studied in a Phase 1 clinical trial and is not approved for any indication based on the available data.
Nitrofurantoin Macrocrystals is developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the company responsible for the drug's development.
Nitrofurantoin Macrocrystals is in Phase 1 clinical development. One Phase 1 trial has been completed, and there are currently no active trials. The drug is investigational and has not been approved by the FDA for any indication.
Nitrofurantoin Macrocrystals has been studied in one completed Phase 1 trial: NCT00649506, titled "Food Study of Nitrofurantoin Macrocrystals 100 mg Capsules and Macrodantin® 100 mg." The trial enrolled 28 healthy adult volunteers in the United States and was active-controlled and randomized.